Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Armed Forces Capital Hospital, Seongnam, Republic of Korea.
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Sci Rep. 2021 May 7;11(1):9784. doi: 10.1038/s41598-021-89182-8.
The mortality rates of COVID-19 vary across the globe. While some risk factors for poor prognosis of the disease are known, regional differences are suspected. We reviewed the risk factors for critical outcomes of COVID-19 according to the location of the infected patients, from various literature databases from January 1 through June 8, 2020. Candidate variables to predict the outcome included patient demographics, underlying medical conditions, symptoms, and laboratory findings. The risk factors in the overall population included sex, age, and all inspected underlying medical conditions. Symptoms of dyspnea, anorexia, dizziness, fatigue, and certain laboratory findings were also indicators of the critical outcome. Underlying respiratory disease was associated higher risk of the critical outcome in studies from Asia and Europe, but not North America. Underlying hepatic disease was associated with a higher risk of the critical outcome from Europe, but not from Asia and North America. Symptoms of vomiting, anorexia, dizziness, and fatigue were significantly associated with the critical outcome in studies from Asia, but not from Europe and North America. Hemoglobin and platelet count affected patients differently in Asia compared to those in Europe and North America. Such regional discrepancies should be considered when treating patients with COVID-19.
COVID-19 的死亡率在全球范围内存在差异。虽然已知疾病预后不良的一些危险因素,但怀疑存在地区差异。我们从 2020 年 1 月 1 日至 6 月 8 日的各种文献数据库中,回顾了根据感染患者所在地,预测 COVID-19 严重结局的危险因素。候选预测结果的变量包括患者的人口统计学特征、基础医学状况、症状和实验室发现。总体人群中的危险因素包括性别、年龄和所有检查出的基础医学状况。呼吸困难、厌食、头晕、乏力和某些实验室发现也是严重结局的指标。亚洲和欧洲的研究表明,基础呼吸疾病与严重结局的风险增加相关,但北美洲没有。欧洲的研究表明,基础肝脏疾病与严重结局的风险增加相关,但亚洲和北美洲没有。亚洲的研究表明,呕吐、厌食、头晕和乏力等症状与严重结局显著相关,但欧洲和北美洲没有。血红蛋白和血小板计数在亚洲和欧洲及北美洲的患者中影响不同。在治疗 COVID-19 患者时应考虑到这些区域性差异。